# AI Venture Spec

## Name:
**GastroenterologyAI - GI Prior Auth & Infusion Platform**

## Core Concept:
AI-powered platform for gastroenterologists that automates biologic prior authorization for Crohn's disease and ulcerative colitis, infusion billing, endoscopy prior authorization, and IBD (inflammatory bowel disease) documentation.

## Problem:
- **12,000+ gastroenterologists** in US
- **GI biologics = $10K-$50K annually**: Remicade, Humira, Entyvio, Stelara, Skyrizi
- **Prior authorization burden**: 80%+ of GI biologics require prior auth (growing)
- **Step therapy**: Fail-first protocols delay treatment (disease progression, colon damage)
- **Infusion billing**: J-code billing for Remicade, Entyvio requires complex documentation
- **Endoscopy prior auth**: Colonoscopy, EGD, flexible sigmoidoscopy = prior auth growth

## Target Vertical:
**Primary:** Gastroenterology Practices
- General gastroenterologists
- IBD specialists (Crohn's, ulcerative colitis)
- Infusion centers (GI-focused)
- Hospital-based GI departments

**Secondary:** Infusion pharmacies, biologic manufacturers, IBD patients

## Why Now:
1. **IBD epidemic**: 3M+ Americans with IBD (Crohn's, UC) - growing
2. **Biologic explosion**: New GI biologics (Skyrizi, Rinvoq, Zeposia) = more prior auth
3. **Step therapy crisis**: Insurers requiring fail-first (5-ASA failure before biologic)
4. **Infusion growth**: Site of care shift (hospital to infusion center) = growth
5. **Colonoscopy screening**: Prior auth growth for screening colonoscopy

## AI Advantage:
- **Biologic prior auth automation**: AI completes GI biologic prior auth (AGA guidelines, clinical criteria)
- **Step therapy navigation**: AI identifies step therapy exceptions, generates appeals
- **Infusion billing optimization**: AI maximizes J-code billing, minimizes waste
- **IBD disease activity scoring**: AI calculates Mayo Score, SES-CD (endoscopic severity)
- **Endoscopy prior auth**: AI completes colonoscopy, EGD prior auth (screening vs. diagnostic)
- **Biosimilar substitution**: AI identifies cheaper biosimilars (Remicade → Inflectra)

## Viral Mechanism:
- **AGA conferences**: American Gastroenterological Association annual meeting
- **IBD community**: Crohn's & Colitis Foundation, patient support groups
- **Infusion center networks**: Sharing best practices
- **Case studies**: "Got biologic approved 50% faster using AI"
- **Patient advocacy**: Crohn's & Colitis Foundation, patient groups

## Revenue Model:
**Per-Practice Subscription:**
- **Solo**: $1,200/month - 1-3 gastroenterologists, prior auth automation
- **Practice**: $3,000/month - 4+ gastroenterologists, infusion billing + step therapy
- **Enterprise**: $7,000/month - Multi-location + white-label + EMR integration

**Per-Prior-Auth add-on:**
- $50 per complex prior auth (beyond included tiers)

**Implementation:**
- $5,000 one-time (payer rule setup, infusion billing setup, training)

**Unit Economics:**
- CAC: $150 (AGA conferences, gastroenterology partnerships)
- LTV: $64,800 (36-month retention - switching costs high)
- Gross Margin: 82%

## Moat:
1. **GI expertise**: IBD protocols, Mayo Score, SES-CD, biologic prior auth criteria
2. **Payer rules**: Each payer has different GI biologic prior auth criteria
3. **AGA guidelines**: American Gastroenterological Association treatment guidelines
4. **Infusion billing**: J-code billing for Remicade, Entyvio, Stelara
5. **Biosimilars**: GI biosimilars = substitution rules, prior auth

## MVP in 12 Weeks:
**Weeks 1-3:**
- Focus: Top 3 GI biologics only (Remicade, Humira, Entyvio)
- ONE payer (UnitedHealthcare)
- Manual workflow

**Weeks 4-6:**
- Build AI GI biologic prior auth completer (UHC criteria)
- Step therapy exception identifier
- Mayo Score calculator (IBD severity)

**Weeks 7-9:**
- Partner with 3 gastroenterology practices
- Deploy pilot for top 3 biologics + UHC
- Validate: Prior auth approval rate, time to treatment

**Weeks 10-12:**
- Add 5 more payers (Aetna, Cigna, Humana, BCBS, Medicare)
- Infusion billing module
- Prepare AGA conference demo

**Validation Metrics:**
- 70%+ prior auth approval rate (vs. 50-60% baseline)
- 60%+ reduction in prior auth time
- 2+ practices commit after pilot
- One step therapy exception granted using AI appeal

## Tech Stack:
- **Backend**: Python/FastAPI
- **AI**: GPT-4 (prior auth completion, appeal letters), Custom ML (payer rule tracking)
- **Integrations**: Gastroenterology EMRs, payer portals, infusion management systems
- **Infrastructure**: AWS (US regions, HIPAA compliant)

## Monthly Revenue Potential (Year 1–3):
- **Year 1**: $14.4K MRR (12 practices × $1.2K ARPU)
- **Year 2**: $72K MRR (60 practices + practice tier)
- **Year 3**: $216K MRR (180 practices + enterprise)

## Risk Factors:
1. **Payer rules**: GI biologic prior auth criteria change frequently
2. **Biosimilar competition**: Biosimilars = cheaper, but prior auth still required
3. **Step therapy**: Insurers tightening fail-first requirements
4. **Competition**: Existing GI EHRs (GI Leap, Modernizing Medicine) adding features
5. **J-code changes**: Infusion billing codes may change

## Competitive Threat:
- **OncologyPriorAuthAI**: Similar model (oncology prior auth) - potential expansion
- **RheumatologyAI**: Similar model (biologic prior auth) - potential expansion
- **SamaCare**: Prior auth platform (oncology focus, could expand to GI)
- **GI EHRs**: Modernizing Medicine GI (not prior auth focused)

**Differentiation**: Only AI platform for gastroenterology with GI biologic prior auth, IBD disease scoring, and infusion billing.

---

## Agent Evaluation Summary

**Score: 8.3/10 - PURSUE** ⭐ **TOP CYCLE 32**

**Strengths:**
- **12,000+ gastroenterologists**: Specialized market
- **$10K-$50K biologics**: High-cost treatments = prior auth burden
- **IBD epidemic**: 3M+ Americans with Crohn's/UC
- **Prior auth explosion**: 80%+ require prior auth
- **Step therapy pain**: Fail-first = disease progression
- **AGA guidelines**: Standardized treatment criteria

**Weaknesses:**
- Payer rules change frequently
- Biosimilar competition
- GI EHR competition

**Why this scores 8.3:**
- **$10K-$50K biologics** = high stakes
- **80% prior auth rate** = massive pain
- **3M+ IBD patients** = growing market
- **Step therapy** = delay = colon damage
- **Specialized** = gastroenterology-specific

**Strong gastroenterology opportunity.**

## Go/No-Go Decision: **GO** ✅

**Critical success factors:**
1. Hire gastroenterologists/IBD specialists as co-founders/advisors
2. Start with top 3 GI biologics (Remicade, Humira, Entyvio)
3. Partner with AGA for distribution
4. Build step therapy exception module (key differentiator)
5. Add infusion billing module (revenue optimization)

**Excellent gastroenterology prior authorization opportunity.**
